Article Details

Adaptimmune Therapeutics Target of Unusually High Options Trading (NASDAQ:ADAP)

Retrieved on: 2025-10-10 05:20:05

Tags for this article:

Click the tags to see associated articles and topics

Adaptimmune Therapeutics Target of Unusually High Options Trading (NASDAQ:ADAP). View article details on hiswai:

Excerpt

Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after buying an additional 19,146 shares in the ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo